Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now!
about
Factors that influence current tuberculosis epidemiologyStructural and functional analysis of the transcriptional regulator Rv3066 of Mycobacterium tuberculosisThe antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosisReduced emergence of isoniazid resistance with concurrent use of thioridazine against acute murine tuberculosis.Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen.Verapamil, and its metabolite norverapamil, inhibit macrophage-induced, bacterial efflux pump-mediated tolerance to multiple anti-tubercular drugs.Host-directed antimicrobial drugs with broad-spectrum efficacy against intracellular bacterial pathogens.Finding alternatives to antibiotics.Combination approaches to combat multidrug-resistant bacteria.Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay.Multidrug and extensively drug-resistant tuberculosis from a general practice perspective.Drug-resistant tuberculosis: emerging treatment options.Targeting bacterial membrane function: an underexploited mechanism for treating persistent infectionsThe role of transport mechanisms in mycobacterium tuberculosis drug resistance and tolerance.Antimicrobial efflux pumps and Mycobacterium tuberculosis drug tolerance: evolutionary considerations.Efflux pumps of Gram-negative bacteria: what they do, how they do it, with what and how to deal with them.Energy metabolism and drug efflux in Mycobacterium tuberculosisMolecular tools for rapid identification and novel effective therapy against MDRTB/XDRTB infections.Drug repositioning in the treatment of malaria and TB.Antituberculosis drug research: a critical overview.New treatment options for multidrug-resistant tuberculosis.Inhibitors of mycobacterial efflux pumps as potential boosters for anti-tubercular drugs.Improving the tuberculosis drug development pipeline.Why and how thioridazine in combination with antibiotics to which the infective strain is resistant will cure totally drug-resistant tuberculosis.Thioridazine in PLGA nanoparticles reduces toxicity and improves rifampicin therapy against mycobacterial infection in zebrafish.Novel non-neuroleptic phenothiazines inhibit Mycobacterium tuberculosis replication.Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis.Evidence of significant synergism between antibiotics and the antipsychotic, antimicrobial drug flupenthixol.Determination of Antipsychotic Drugs Known for Narcotic Action by Ultra Performance Liquid Chromatography
P2860
Q27025298-C28DFDA1-14DB-44FC-9E2C-64A0FCA0A85FQ27670866-01B4CB8C-2DFC-40C4-A4C2-F1A4F6196C5EQ28475461-F8C0E395-5924-44B4-9DB9-18C638AEFB1DQ33798280-20DD2A84-F317-4CD9-87A2-E91FA0579973Q33901935-6D011795-40D2-472E-B9CA-609283878C79Q33947806-0E3193B1-079F-4136-95F4-60CBE49262DEQ34026297-1125D057-A380-4B6F-8F91-B285AA571DA3Q34426004-D688E77A-C2FE-4D1F-9CBA-693DE34C19E9Q34554879-40FF4B71-09B1-42A1-AC50-F55E5C4FF105Q34781823-7F830287-DC32-44B0-8241-2BE8C5686153Q35026558-91FBBC73-38A1-42D0-8EB5-C25F04CA6198Q35683967-8A8A7B10-BFFD-4201-9F77-349E4922490CQ36393640-374CA2DF-D8CA-4B3D-A697-035E77CC4301Q37277325-5C3EB535-AACF-4914-A237-19380E232330Q37385024-F688154A-A0CC-4FB3-8AC1-957FE7A2B46CQ37428456-80B9901F-75EE-433E-96D9-920ECBB3CFACQ37712986-CDC99CB9-DBC4-4539-984A-9F0123D49207Q37727181-7F480325-491E-4541-9750-F349B3DC71A2Q37924298-1BE89585-8327-462B-9FEB-CC5F8525E8AAQ38012651-CA5FDFE9-AB3E-4224-9207-A61F23F61B27Q38024041-0355F9A9-A959-4C0C-B4F5-20B4A028EBF5Q38056146-03FC5CAE-032D-44D2-BD20-AEA7E4C59FD6Q38378647-A8C756CF-2035-4E38-A148-D82F86077EFDQ38872081-CB25DF98-4B3A-445A-8CBF-4C776A45C550Q40316822-A55EF706-DCCC-4D65-9DA7-F893688EFF26Q42227061-452D7C7F-2ACA-4315-B41C-48413D80DF56Q42858670-32BC24BE-FDAC-4D02-97B4-3EF4DE6E3EEAQ50035189-E220EC9F-62BC-44A4-B537-67882D461DA2Q58289710-9A0A29D9-224B-404E-A439-8B1CD630D267
P2860
Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now!
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Thioridazine cures extensively ...... need for global trials is now!
@ast
Thioridazine cures extensively ...... need for global trials is now!
@en
Thioridazine cures extensively drug-resistant tuberculosis
@nl
type
label
Thioridazine cures extensively ...... need for global trials is now!
@ast
Thioridazine cures extensively ...... need for global trials is now!
@en
Thioridazine cures extensively drug-resistant tuberculosis
@nl
prefLabel
Thioridazine cures extensively ...... need for global trials is now!
@ast
Thioridazine cures extensively ...... need for global trials is now!
@en
Thioridazine cures extensively drug-resistant tuberculosis
@nl
P2093
P1476
Thioridazine cures extensively ...... need for global trials is now!
@en
P2093
Martin J Boeree
Stephen H Gillespie
Zarir F Udwadia
P304
P356
10.1016/J.IJANTIMICAG.2009.12.019
P577
2010-02-25T00:00:00Z